US HB937 | 2019-2020 | 116th Congress

US Congress House Bill 937 (Prior Session Legislation)

Status

Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on January 31 2019 - 25% progression, died in committee
Action: 2019-01-31 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

Title

Right Rebate Act of 2019

History

Date	Chamber	Action
2019-01-31	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-01-31	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-01-31	House	Referred to the Subcommittee on Health.
2019-01-31	House	Introduced in House

Same As/Similar To

SB205 (Related) 2019-01-24 - Read twice and referred to the Committee on Finance.
HB1839 (Related) 2019-04-18 - Became Public Law No: 116-16. (TXT | PDF)